Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its price objective reduced by Mizuho from $4.00 to $3.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock. A number of other equities research analysts have also weighed in on the company. The Goldman Sachs Group […]
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) was downgraded by investment analysts at SVB Leerink from an “outperform” rating to a “market perform” rating in a research note issued to investors on Monday, Marketbeat Ratings reports. AMLX has been the topic of a number of other reports. The Goldman Sachs Group reissued a “neutral” rating […]
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) saw unusually large options trading activity on Friday. Stock investors purchased 9,214 call options on the stock. This is an increase of approximately 224% compared to the average daily volume of 2,843 call options. Wall Street Analysts Forecast Growth Several brokerages recently commented on AMLX. The Goldman […]
Primecap Management Co. CA purchased a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 304,900 shares of the company’s stock, valued at approximately $5,583,000. Primecap Management Co. CA owned […]
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.03, Yahoo Finance reports. Amylyx Pharmaceuticals had a return on equity of 0.49% and a net margin of 0.62%. The firm had revenue […]